Financial Data and Key Metrics Changes - In Q2 2025, total revenue increased by 29% year over year to $25.4 million, driven by a 28% increase in cell processing revenue [16][6] - Adjusted EBITDA margin expanded by 400 basis points to 24%, reflecting strong operating leverage [6] - GAAP net loss was $15.8 million or $0.33 per share, compared to a net loss of $5.6 million or $0.12 per share in the prior year [20][16] Business Line Data and Key Metrics Changes - Cell processing revenue reached $23 million, marking a 28% year-over-year increase and a 6% sequential increase [8] - Biopreservation media (BPM) products accounted for approximately 85% of Q2 cell processing revenue, with top 20 customers contributing about 80% of BPM revenue [8][9] - Adjusted operating expenses totaled $16.9 million, up from $14 million in the prior year, largely due to increased stock-based compensation and IPR&D expenses related to the Panthera acquisition [19][16] Market Data and Key Metrics Changes - At the end of Q2, BPM products were embedded in 16 approved therapies and used in over 250 relevant commercially sponsored CGT trials in the U.S., representing over a 70% market share [10] - The company maintains a strong position in late-stage clinical development, with nearly 80% market share in Phase 3 clinical trials [10] Company Strategy and Development Direction - The company is focused on operational execution and disciplined capital allocation, with a sharpened focus on its product portfolio and market share in cell processing [7] - A strategic investment in Pluristics was made to explore product portfolio expansion into relevant adjacencies [12] - The company raised its full-year revenue guidance to $100 million to $103 million, reflecting a growth of 22% to 25% [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macro uncertainties, citing strong visibility from major customers [26] - The FDA's recent decision to remove the REMS requirement is viewed as a positive development for the CGT landscape, potentially enhancing patient access to therapies [13] - The company expects continued strength in cell processing revenue despite broader market uncertainties [7] Other Important Information - The company reported cash and marketable securities of $100.2 million at the end of Q2 2025 [21] - The acquisition of Panthera is expected to enhance market leadership in biopreservation and introduce new product lines [54] Q&A Session Summary Question: Guidance visibility and commercial ramps - Management indicated good visibility into revenue from top customers and expressed confidence in the second half of the year despite potential lumpiness between Q3 and Q4 [26][27] Question: Cross-selling dynamics - Management noted early traction in cross-selling efforts, with larger accounts showing interest in additional products [31] Question: CryoCase timeline - Management is in discussions with a large customer regarding changes to the CryoCase and has over 30 customers evaluating it [35] Question: Pluristics investment and competition - Management does not view Pluristics as a competitive threat but is interested in their assay development capabilities [40] Question: Panthera updates - The company remains on track to have commercial products from Panthera in the market by the second half of next year [42] Question: Demand trends in early clinical stages - Management noted a slight softness in demand from smaller Phase I and II customers but expects overall growth to continue [49] Question: Distribution channel visibility - Management has not seen any weakness in the distribution channel and remains confident in its strength for the remainder of the year [53] Question: M&A strategy - The company emphasizes a disciplined approach to M&A, focusing on strategic rationale and market leadership [60]

Financial Data and Key Metrics Changes - In 2024, revenue increased by 12% to $6.15 billion, adjusted EBITDA grew by 14% to $2.24 billion, and AFFO increased by 11% to $1.3 billion [8][42][56] - For Q4 2024, revenue was $1.58 billion, up 11% year-on-year, adjusted EBITDA reached $605 million, up 15%, and AFFO was $368 million, up 12% [37][41][56] Business Line Data and Key Metrics Changes - Records and Information Management (RIM) business grew by 7% in 2024, with Q4 revenue of $1.26 billion, an increase of $66 million year-on-year [15][44] - Data Center revenue grew by 25% to a record $620 million in 2024, with Q4 revenue of $170 million, up 24% year-on-year [22][47] - Asset Lifecycle Management (ALM) revenue increased by 119% in 2024, with Q4 revenue of $112 million, up 118% year-on-year [27][51] Market Data and Key Metrics Changes - The growth portfolio, including digital solutions and data center management, represented 25% of total revenue in 2024, up from 15% at the beginning of the Matterhorn initiative [12] - The company secured significant contracts across various sectors, including a four-year contract with a Fortune 500 company for records management and additional services [16] Company Strategy and Development Direction - The company aims to continue double-digit growth driven by recurring revenue streams and strong macro factors supporting demand for growth businesses [14] - A focus on cross-selling to a loyal customer base, which includes 95% of the Fortune 1000, is a key strategy for growth [14] - The company has authorized a 10% increase in its quarterly dividend, reflecting confidence in future performance [14][55] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving consolidated growth in excess of 10% for the foreseeable future, supported by strong demand and operational efficiencies [13][14] - The company anticipates another record year in 2025, with revenue projected between $6.65 billion and $6.8 billion, representing year-on-year growth of 9% at the midpoint [56][57] Other Important Information - The company has a strong balance sheet with net lease adjusted leverage at 5.0 times, the lowest level since its REIT conversion in 2014 [54] - The company is focused on improving profitability in its Consumer Storage business, which has been deemphasized in favor of more profitable segments [102][105] Q&A Session Summary Question: Can you elaborate on how organic growth in the ALM business in 4Q was split between volumes and component prices? - Management indicated that organic growth was largely volume-driven, with component prices remaining generally flat [63][66] Question: What's your expectation for RIM volumes in Q1 and the balance of 2025? - Management expects RIM volumes to be flat to slightly up, with mid-single-digit overall revenue growth anticipated [71][72] Question: Can you discuss the implications of the DeepSeek announcement on the Data Center business? - Management noted strong pipeline activity and did not foresee any reduction in CapEx expenditure from large customers despite market noise [78][82] Question: What drove the churn in Q4 and what are your expectations for 2025? - Management explained that churn was due to a couple of long-term clients moving to cloud solutions, but overall churn is expected to be below historical levels in 2025 [94][95] Question: Can you provide insights on cash renewal spreads and capital recycling in your data center portfolio? - Management expects cash renewal spreads to continue rising due to demand outpacing supply, and noted no specific plans for capital recycling at this time [120][121]